Oncobiologics (OTLK) Expected to Announce Quarterly Earnings on Friday

Oncobiologics (NASDAQ:OTLK - Get Free Report) is projected to release its Q4 2025 results before the market opens on Friday, December 26th. Analysts expect Oncobiologics to post earnings of ($0.23) per share and revenue of $5.8460 million for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, December 24, 2025 at 4:00 PM ET.Get Oncobiologics alerts:Oncobiologics Trading Down 8.8%3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices OTLK stock opened at $2.07 on Friday. The stock has a market cap of $91.95 million, a P/E ratio of -3.63 and a beta of 0.17. Oncobiologics has a twelve month low of $0.79 and a twelve month high of $3.39. The company's 50 day moving average is $1.62 and its two-hundred day moving average is $1.66. Analyst Ratings ChangesSeveral equities analysts have issued reports on the company. Guggenheim lowered Oncobiologics from a "buy" rating to a "neutral" rating in a report on Thursday, August 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oncobiologics in a research report on Monday, December 8th. Ascendiant Capital Markets dropped their price target on Oncobiologics from $21.00 to $8.00 and set a "buy" rating on the stock in a research note on Monday, September 22nd. Zacks Research cut Oncobiologics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 27th. Finally, HC Wainwright restated a "neutral" rating on shares of Oncobiologics in a research report on Tuesday, September 30th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $6.50.MarketBeat Week in Review – 6/17 - 6/21Get Our Latest Stock Analysis on OncobiologicsInstitutional Investors Weigh In On OncobiologicsSeveral institutional investors have recently modified their holdings of OTLK. Russell Investments Group Ltd. increased its stake in Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company's stock valued at $39,000 after purchasing an additional 21,941 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock valued at $126,000 after purchasing an additional 44,063 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock valued at $103,000 after buying an additional 25,351 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company's stock. About Oncobiologics (Get Free Report)Outlook Therapeutics: Analysts Forecast Over 500% Stock UpsideOutlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.Recommended StoriesFive stocks we like better than OncobiologicsWith Risk Tolerance, One Size Does Not Fit AllBroadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500Why Are Stock Sectors Important to Successful Investing?Forget the Chips: 4 Industrial Plays for the AI ReboundWhat Are Dividend Achievers? An IntroductionMongoDB Could Hit Record Highs—But You’ll Need to Move FastThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Oncobiologics Right Now?Before you consider Oncobiologics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncobiologics wasn't on the list.While Oncobiologics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here